Public Profile

Geron Corporation

Geron Corporation, a pioneering biotechnology firm headquartered in the United States, focuses on developing innovative therapies for cancer and other serious diseases. Founded in 1990, Geron has made significant strides in the field of telomerase biology, positioning itself as a leader in the development of telomerase inhibitors. The company’s flagship product, imetelstat, is a first-in-class telomerase inhibitor that targets cancer stem cells, offering a unique approach to treating various malignancies. Geron’s commitment to advancing cancer treatment has garnered attention within the industry, as it continues to explore new therapeutic avenues and expand its operational reach. With a strong emphasis on research and development, Geron Corporation remains at the forefront of biopharmaceutical innovation, striving to improve patient outcomes in oncology.

DitchCarbon Score

How does Geron Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

18

Industry Average

Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

19

Industry Benchmark

Geron Corporation's score of 18 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.

52%

Geron Corporation's reported carbon emissions

Geron Corporation, headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. Without emissions figures, it is challenging to assess their carbon footprint or climate commitments. However, the absence of data may indicate a need for enhanced transparency in their environmental strategies. As the industry increasingly prioritises sustainability, Geron Corporation may benefit from establishing clear climate goals and reporting mechanisms to align with best practices in emissions management.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Geron Corporation's primary industry is Health and social work services (85), which is low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. Geron Corporation is headquartered in US, which has a rank of low, indicating low grid carbon intensity.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Geron Corporation is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
Carbon Disclosure Project
The Climate Pledge
UN Global Compact

Similar Organizations

BioMarin

US
Chemicals nec
Updated 6 days ago

Bms

US
Chemicals nec
Updated 6 days ago

CRISPR Therapeutics AG

CH
Health and social work services (85)
Updated 6 days ago

Tissue Genesis, Inc.

US
Research and development services (73)
Updated 6 days ago

PharmaEssentia USA Corporation

US
Chemicals nec
Updated 6 days ago

Vertex Pharmaceuticals

US
Research and development services (73)
Updated 6 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers